ADVFN - Advanced Financial Network.
HOME» NYSE » F » FRX Stock Price » FRX Stock News

Forest Labs Share News

 Forest Laboratories, Inc. Stock Price
FRX Stock Price
 Forest Laboratories, Inc. Stock Chart
FRX Stock Chart
 Forest Laboratories, Inc. Stock News
FRX Stock News
 Forest Laboratories, Inc. Company Information
FRX Company Information
 Forest Laboratories, Inc. Stock Trades
FRX Stock Trades

Icahn: Chesapeake Can Meet Funding Gap by Cutting Costs - CNBC Interview

By Angel Gonzalez Activist investor Carl Icahn said that Chesapeake Energy Corp.'s (CHK) assets are undervalued, and the company's worth is likely to rise in coming years as natural gas becomes more prized. In an interview with CNBC, the activist investor, who has recently become troubled Chesapeake's second-largest shareholder, said that Chesapeake has very good assets, but "they couldn't afford to buy some of them," generating a big funding gap. "They can definitely meet" that gap by cutting costs, he said. The Oklahoma City-based energy company has been under fire from shareholders such as Mr. Icahn, who have questioned the board's loose oversight of Chief Executive Aubrey McClendon. Last month, that sentiment resulted in an overhaul of the board, and Mr. McClendon's separation of his role as chairman. Mr. Icahn, who helped bring about the overhaul, said he isn't going to sell his Chesapeake shares in the short term, as he thinks they will rise in value significantly. "I hope you're going to see a much higher price," he said. Mr. Icahn, who on Monday accused Forest Laboratories Inc.'s (FRX) Chief Executive Howard Solomon of dumping $500 million of stock ahead of the loss of patent exclusivity on antidepressant Lexapro, said that that the drug maker was a "quintessential example of what is wrong with governance" in corporate America. Mr. Icahn has been involved in a long-running battle with Forest Laboratories's board--which was reignited earlier this month when he nominated four candidates to its board--and last week he sued the company in a bid to get more insight on its succession plan. He told CNBC that he would "like to avoid a proxy fight" in his battle with the board. That said, he wouldn't support selling the company. "Not at this point," Mr. Icahn said. "You can't do it at this point." Write to Angel Gonzalez at angel.gonzalez@dowjones.com

Stock News for Forest Labs (FRX)
DateTimeHeadline
01/15/201309:05:33U.S. HOT STOCK FUTURES: HOT STOCKS TO WATCH
08/27/201218:30:14Forest Labs Unveils Shareholder-Rights Plan
08/15/201212:00:17Forest Labs Shareholders Reelect 9 Board Members
08/13/201219:30:30Icahn Criticizes Forest Labs on FDA Warning Letter
08/09/201216:50:36Forest Labs Agrees to Corporate-Governance Changes
07/24/201210:40:03Icahn Sounds The Alarm on Forest Labs
07/23/201217:00:23FDA Approves Forest Laboratories' Tudorza Pressair
07/16/201208:30:23Forest Labs Finds Fault with Icahn Slate
07/09/201212:14:53CORRECT: Applications Given Early Antitrust Clearance
07/09/201212:01:05Applications Given Early Antitrust Clearance
07/02/201221:10:33Icahn Says Chesapeake Can Meet Funding Gap by Cutting Costs
07/02/201218:09:12Icahn: Chesapeake Can Meet Funding Gap by Cutting Costs - CNBC...
07/02/201215:30:10Icahn Accuses Forest Labs CEO of $500 Million Stock Dump
06/19/201215:10:12Icahn Nominates Four to Forest Laboratories Board
04/17/201208:55:35Forest Labs 4Q Net Falls 40% As Lexapro Patent Expires; Has Upbeat...
04/02/201209:10:09Forest Laboratories Buys Blood Pressure Drug Bystolic From Janssen...
03/14/201217:10:09Watson Pharma Seeks FDA Approval of Generic Version Of Bystolic
03/14/201214:58:34Teva Receives FDA Approval For Generic Lexapro For Adults
03/14/201214:02:40Forest Labs, Janssen Sue Several Drug Makers Over Bystolic
02/21/201211:28:23FDA: Forest Labs Lung Drug Effective For COPD; Raises Concerns

Forest Labs and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad